Noppakun N, Phuphaibool K
Division of Dermatology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
J Med Assoc Thai. 1992 Feb;75(2):99-103.
Thirty patients with the clinical and laboratory proven diagnosis of either tinea corporis or tinea cruris were treated with a new systemic antifungal agent, itraconazole. Itraconazole, a triazole derivative, interacts specifically with fungal cytochrome P-450 and has high affinity for skin and mucous membrane. In this open non-comparative clinical trial, itraconazole was given orally in the dosage of 100 mg per day for 14 consecutive days. Twenty-nine cases (96.6%) had good clinical response with 83.3 per cent mycological cure rate. Complete healing of cutaneous lesions was 56.6 per cent at the end of therapy (14 days) and increased to 83.3 per cent two weeks later. No significant side effects were noted. Itraconazole is highly effective in treatment of dermatophytosis with a shorter treatment period than other conventional antifungal agents.
30例经临床和实验室确诊为体癣或股癣的患者接受了一种新型全身用抗真菌药伊曲康唑的治疗。伊曲康唑是一种三唑衍生物，可与真菌细胞色素P - 450特异性相互作用，对皮肤和黏膜具有高亲和力。在这项开放性非对照临床试验中，伊曲康唑以每日100mg的剂量口服，连续服用14天。29例（96.6%）患者有良好的临床反应，真菌学治愈率为83.3%。治疗结束时（14天）皮肤损害的完全愈合率为56.6%，两周后增至83.3%。未观察到明显的副作用。伊曲康唑治疗皮肤癣菌病高效，且治疗周期比其他传统抗真菌药短。
